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Abstract
Purpose: The aim of this study was to estimate local confidence limit for 6 MVphoton beam based intensity modulated radiation therapy (IMRT) using TG119test protocol. Methods: The American Association of Physicists in Medicine(AAPM) Task Group 119 (TG119) prescribed a protocol to evaluate overallaccuracy of IMRT system rather than independent uncertainty in dose calculation,dose delivery and measurement system. Two preliminary and five clinical testcases were created based on dose prescriptions and planning objectives given byTG119 report. Verification plans were created in a planning slab phantom, 2DMatrix dosimetry system (I’MatriXX) with multicube phantom and aS-1000electronic portal imaging device (EPID). Radiation absorbed doses to high dosepoints in the planning target volume (PTV) region and low dose points inavoidance structures were measured using CC13 ionization chamber havingsensitive volume of 0.13 cm3. The measured and planned doses were normalizedwith respect to their prescription doses and intercompared. The gamma analysiswas carried out for both I’MatriXX and EPID, adopting the acceptance criteria of 3%DD (dose difference) and 3 mm DTA (distance to agreement) with 10% thresholddose. Results: For the point dose measurements with ion chamber, the averagedose difference ratio in high dose low gradient PTV region was -0.0133 ± 0.012corresponding to a confidence limit of 0.037. The average dose difference in lowdose region (avoidance structure) was -0.00004 ± 0.010 corresponding to aconfidence limit of 0.021. The average percentage of points passing the gammacriteria of 3% DD and 3 mm DTA for composite planar dose distribution measuredby I’MatriXX was 99.47 ± 0.43 which corresponds to a confidence limit of 1.38 (i.e.98.62% passing). Similarly, the average percentage of points passing the gammacriteria of 3% DD and 3 mm DTA for per-field dose distribution measured by EPIDwas 98.00 ± 2.49 which corresponds to a confidence limit of 6.87. Conclusion: Ourresults were well within action level given by AAPM TG119 report throughmulti-institutional study providing us adequate confidence in delivering IMRTtreatment.
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1. IntroductionThe intensity modulated radiation therapy (IMRT) is apromising treatment technique having advantage ofdelivering highly conformal dose distribution to targetvolume and sparing of organs at risk. However, stringentquality assurance programme is required to beinstituted in dose calculation, dose delivery andmeasurement system for effective and safe clinicalimplementation of this technique. Many medicalphysicists have already studied dosimetric1 performance
of multileaf collimator (MLC) for different modality oftreatments.2,3 The AAPM report on IMRT commissioningpublished4 in 2003 and its further extension by AAPMTG1195 has helped us not only in quantifying the overallperformance of an IMRT system but also providedreasonable confidence limits (CLs) for assessing theadequacy of the dosimetric commissioning. However, avery few papers have demonstrated the usefulness ofAAPM TG119 IMRT test protocol in the estimation of
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local confidence limits.6,7 We implemented TG119protocol for 6 MV photon beam in our institute in orderto get local confidence to check overall accuracy of IMRTsystem. All the test cases, head-and- neck, prostate,C-shape easy, C-shape hard and multi target werecreated in a local slab phantom and treatment planningwas carried out using Eclipse radiotherapy treatmentplanning system. The purpose of this study was to findout local confidence limit and compare the results withthe action level given by AAPM TG119 through multi-institutional study.
2. Methods and MaterialsThis study was performed using 6 MV photon beam ofour Novalis Tx (Varian Medical Systems, Palo Alto, USA)linear accelerator equipped with high definition MLC(HD120 MLC). Water equivalent plastic phantom (SP34,
solid water, IBA dosimetry) having dimension of 30 × 30× 15 cm3 was used for the implementation of AAPMTG119 prescribed tests. As the phantom is having 15 cmthickness, it is possible to position the ionizationchamber at its center for dosimetric measurements.AAPM TG119 test protocol consists of two preliminarytests to evaluate the accuracy of dose calculation moduleand five clinical test cases concerned with a range ofoptimization problems requiring simple to complexmodulation patterns. In the first preliminary test (Test1), parallel-opposed 10 × 10 cm2 fields were used todeliver 2 Gy to the mid-plane of the phantom. For thesecond preliminary test (Test 2), 15 cm long parallelopposed anterior-posterior (AP-PA) fields were createdby the MLC with a set of five bands each having 3 cmwidth to deliver 25 monitor unit (MU).
Figure1: AAPM TG119 mock prostate structures.
Figure 2: Dose distributions of C-shape easy and C-shape hard treatment plans.
Figure 3: Dose volume histograms (DVH) of C-shape easy and C-shape hard treatment plans generated using Eclipsetreatment planning system.
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For all clinical test cases (head-and-neck, prostate,C-shape easy, C-shape hard and multi-target) CT and RTstructures were downloaded fromhttp://www.aapm.org/pubs/tg119/default.asp.The target and normal structures were created byregistering the center of the CT of the local phantom tothat of the downloaded phantom and then transferredthese structures to the local phantom (Figure 1) forplanning in Eclipse treatment planning system byanisotropic analytical algorithm (Version 10). Figure 2shows the axial plane dose distributions and Figure 3shows the dose volume histograms (DVH) of C-shapeeasy and C-shape hard treatment plans generated by theEclipse TPS. The prescribed doses for head-and-neck,C-shape easy, C-shape hard and multi-target test caseswere 50 Gy (2 Gy × 25 fractions) and for the prostatecase it was 75.6 Gy (1.8 Gy × 42 fractions). Thetreatment plans for head-and-neck and C-shape testshad nine treatment fields at 40° angular intervals of thegantry with respect to its vertical position. However, thetreatment plans for prostate and multi-target tests hadseven fields at 50° angular intervals of the gantry withrespect to its vertical position. These test plans werecreated as per dose prescriptions and planningobjectives specified in AAPM TG119 report. Verificationplans were created in a planning slab phantom, 2DMatrix dosimetry system with multicube phantom andaS1000 electronic portal imaging device (EPID). Theevaluations of the results were carried out in terms ofthe confidence limits defined in AAPM TG119 report.Following definitions of the confidence limits (CLs) forthe point and planar dose measurements were used.CLpoint = M ± 1.96σ (1)CLplanar = (100 - M) ± 1.96σ (2)where, M and σ are the mean value and the standarddeviation of the measured data, respectively.
2.1 Point dose measurementDoses to high dose points in the planning target volume(PTV) region and low dose points in avoidancestructures were measured using CC13 ionizationchamber (IBA Dosimetry GmbH, Schwarzenbruck,Germany) having sensitive volume of 0.13 cm3 which isclosed to specification given by AAPM TG119 for suchmeasurements. The measured and planned doses werenormalized with respect to their prescription doses andintercompared. Necessary care was taken in positioningthe ionization chamber during measurement of pointdose as sub-millimeter variation may vary the resultsignificantly.
2.2 Fluence measurementI’MatriXX (IBA dosimetry, Schwrazenbruck, Germany)with multi-cube phantom was used for composite planardose measurement.8 I’MatriXX is a two dimensionalarray of dosimeters consisting of 1020 vented ionizationchamber each having sensitive volume of 0.08 cm3. The
ionization chambers are arranged in a 24 × 24 cm2 areaeach having diameter 4.5 mm, height 5 mm and 3.6 mmwater equivalent thickness on the front side. Thedistance between each ionization chamber is 0.76 cm.The calibration of I’MatriXX was performed as permanufacture recommended procedure. All the test planswere executed at gantry angle 00 and results wereanalyzed using OmniPro IMRT software (IBA dosimetry,V 1.76). Coronal isocenter plane was used for comparingI’MatriXX measured dose distribution with thetreatment planning system (TPS) calculated dosedistribution for the entire test plans. Planar dosedistribution calculated by TPS was converted into 0.76cm × 0.76 cm matrix to match the dose distributionresolution with the resolution of I’MatriXX. The TPScalculated and I’MatriXX measured dose matrices wererescaled to 0.1 cm resolution using interpolationsoftware provided by OmniPro IMRT software. Themeasured and planned dose distribution was comparedby gamma analysis9,10,11 adopting the acceptabilitycriteria of 3% dose difference (DD) and 3 mm distanceto agreement (DTA). To avoid the very low dose region,the threshold dose was set in OmniPro IMRT software as10%.
2.3 Per field dose measurementIn this study, we used portal dosimetry tools for qualityassurance of four IMRT test plans. The multi-target planwas excluded from per field dose measurement usingEPID. Gamma analysis of planar dose distribution wasdone by comparing portal dose prediction (PDP) andmeasured dose by EPID using PDP software. The dosedistribution to each of the field was measured by highresolution aSi1000 EPID (Varian portal Vision aS1000).The EPID is made up of array of light sensitiveamorphous-Si photodiodes arranged in 40 × 30 cm2active area with a matrix of 1024 × 768 pixels whichgives resolution of 0.039 × 0.034 mm per pixel pitch. Wecommissioned aSi1000 EPID as per requirement of PDPalgorithm in Eclipse treatment planning system forportal dosimetry. The EPID calibration process detailswere out of the scope of the present study. EPID imageswere acquired for the entire IMRT field at an SDD of 105cm. Several studies have been done on dose responsecharacteristics of the detector and gamma comparisonwith 2D array detector for IMRT.12,13 All the test planswere exposed at planned gantry angle and results wereanalyzed using PDP software. The gamma analysis wasdone adopting the acceptability criteria of 3% DD, 3 mmDTA and 10% threshold dose which effectively limits theevaluation within collimator jaws and absolute globalnormalization to the maximum of each dose.
3. Results and DiscussionThe ionization chamber measured and calculated pointdoses for preliminary test 1 at isocenter were 1.99 Gyand 2Gy respectively. Similarly, measured and calculateddoses for preliminary test 2 were 46.54 cGy and 47 cGy
4 Kadam et al.: Confidence limit for 6 MV IMRT beam using TG119 test protocol International Journal of Cancer Therapy and Oncology
www.ijcto.org
© Kadam et al. ISSN 2330-4049
respectively. The percentage of points passing gammacriteria for I’MatriXX measurements were more than99% for both of the preliminary tests (Test 1 and Test 2)which indicate about the goodness of dose deliverysystem for non-IMRT technique.Figure 4 presents a comparison of I’MatriXX measuredand TPS calculated planar dose distribution showinggamma analysis results and line profile agreement formultitarget test plan.Table 1 to 5 shows treatment plan statistics with resultsfor all the clinical plans whereas Figure 5 shows gammaanalysis comparison of PDP calculated and EPID
measured planar dose distributions for Head and Necktest plan.For all clinical test plans, the ionization chambermeasurement results in the high and low dose regionshave been shown in Table 6. The average dose differenceratio in the high dose low gradient PTV region was-0.0133 ± 0.012 corresponding to the confidence limit of0.037. This value is below the AAPM TG119 CL of 0.045.The average dose difference in low dose region(avoidance structure) was -0.00004 ± 0.010corresponding to the confidence limit of 0.021, which isbelow the AAPM TG119 CL of 0.047. Thus, our resultswere below the action levels given by TG119.
Figure 4: Comparison of MatriXX measured and TPS calculated planar dose distribution showing gamma analysis results(bottom left) and line profile agreement (bottom right) for multitarget plan.
Table 1: Treatment plan statistics with results for prostate plan.TG Structureprostate Planningparameters Plan goal(cGy) TG119 resultsmean (cGy) Present studyplan results (cGy)PTV D95 >7560 7566 7614D5 <8300 8143 7982Rectum D30 <7000 6563 5351D10 <7500 7303 7324Bladder D30 <7000 4394 2952D10 <7500 6269 4847
Table 2: Treatment plan statistics with results for multi-target plan.TG StructureMulti-target Planningparameters Plan goal(cGy) TG 119 Resultsmean (cGy) Present studyplan results (cGy)Central target D99 >5000 4955 5030D10 <5300 5455 5261Superior target D99 >2500 2516 2818D10 <3500 3412 3379Inferior target D99 >1250 1407 1616D10 <2500 2418 2063
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Table 3: Treatment plan statistics with results for C-shape (easier) plan.TG structureC-shape(easier) Planningparameters Plan goal(cGy) TG 119 resultsmean (cGy) Present studyplan results (cGy)PTV D95 5000 5010 5009D10 <5500 5440 5265Core D10 <2500 2200 1864
Table 4: Treatment plan statistics with results for C-shape (harder) plan.TG structureC-shape (harder) Planningparameters Plan goal(cGy) TG 119 resultsmean (cGy) Present studyplan results (cGy)PTV D95 5000 5011 5025D10 <5500 5702 5374Core D10 <1000 1630 1452
Table 5: Treatment plan statistics with results for head and neck plan.TG structurehead and neck Planningparameters Plan goal(cGy) TG 119 resultsmean (cGy) Present studyplan results (cGy)PTV D90 5000 5028 5014D95 >4650 4704 4687D20 <5500 5299 5208Cord Maximum <4000 3741 3707Rt Parotid D50 <2000 1798 1856Lt Parotid D50 <2000 1798 1869
Figure 5: Comparison of PDP calculated and EPID measured planar dose distribution showing gamma analysis results (left)and line profile agreement (right) for head and neck test plan.
Table 6: High dose point in the PTV and low dose point in the avoidance structure measured using ionization chamber andthe associated confidence limits.Test Prescribeddose/fr (cGy)(C) Location Measureddose (cGy)(A) Planneddose (cGy)(B) High doseregion(A-B)/C Low doseregion(A-B)/CMulti-target 200 isocenter 203.22 204.6 -0.0069 n/a4cm superior 122.64 126.2 n/an/a -0.01784cm inferior 0.7138 0.754 -0.0002Prostate 180 isocenter 181.0 182.4 -0.0077 n/a2.5 cm posterior 104.08 104.5 n/a -0.0023Head & neck 200 isocenter 199.16 199.6 -0.0022 n/a4cm posterior 0.9495 0.976 n/an/a -0.0001C-shape(easy) 200 isocenter 188.84 187.8 0.00522.5cm anterior 201.76 208.3 -0.0327 n/aC-shape(hard) 200 isocenter 181.90 178.9 n/a 0.0152.5cm anterior 199.0 202.4 -0.017 n/aMeanStandard deviationConfidence limit = (mean) ± 1.96 σ -0.0133 0.00000.0120 0.01070.037 0.021
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Table 7: Percentage of gamma passing for composite planar dose measured using I’MatriXX.Test plans Plane % gamma passing (I’MatriXX)Multi-target isocenter 99.48Prostate isocenter 99.91Head & neck isocenter 99.77C-shape(easy) isocenter 99.39C-shape(hard) isocenter 98.79Mean 99.47Standard deviation 0.43Confidence limit = (100-mean) ±1.96 σ 1.38
Table 8: Percentage of gamma passing for per field measured using EPID.Field Prostate Head & neck C-shape(easy) C-shape(hard)1 100 99.1 94.8 98.72 94.5 99.6 98.8 97.53 99.7 97.3 98.4 98.84 97.8 98.2 100 97.35 97 99.3 99.8 98.66 99.9 99.4 99.8 99.27 87.2 99.7 99.9 96.78 n/a 93.9 97.1 97.29 n/a 99.8 98.1 99.0Mean 96.59 98.48 98.52 98.11Overall mean 98.0Standard deviation 2.49Confidence limit = (100 - mean) ± 1.96σ 6.87We evaluated planar dose distribution at isocenter planeby I’MatriXX array and EPID and the results ofpercentage gamma passing for these methods are shownin Table 7 and Table 8 respectively. The multitarget testplan was excluded for the estimation of confidence limitusing EPID because of poor gamma passing. The reasonfor poor gamma passing in case of EPID may be due toirradiation of large detector areas with a significantfraction of MU causing production of backscatterelectrons from the arm of the detector. However,dosimetric measurements for the multitarget test planswere carried out using I’MatriXX showing gammapassing of 99.48%.The average percentage of points passing the gammacriteria of 3% DD and 3 mm DTA for composite planardose distribution measured by I’MatriXX array was99.47 ± 0.43 which corresponds to the confidence limitof 1.38 (i.e., 98.62% passing). This indicated that thepercentage of points passing the gamma criteria shouldbe more than 98.62%, approximately 95% of the timefor composite planar dose distribution by I’MatriXXarray. Similarly, average percentage of points passingthe gamma criteria of 3% DD and 3 mm DTA forper-field dose distribution measured by EPID was 98 ±2.49. Thus, the corresponding confidence limit was 6.87(i.e., 93.13% passing). This indicated that the percentageof points passing the gamma criteria should be morethan 93.13%, approximately 95% of the time for perfield planar dose distribution by EPID. This proved thatthe results are well within action level given by TG119report.
4. ConclusionThe estimation of local confidence limit using AAPMTG119 is a very useful study to estimate overall accuracyof IMRT system. Estimated confidence limits for pointdose measurements in high dose low gradient PTVregion and in low dose region (avoidance structure)were 0.037 (i.e. 3.7%) and 0.021 (i.e. 2.1%) respectively.The recommended action level given by AAPM TG119Multi-institutional study for point dose measurements interms of CLs were 5% in a high dose low gradient regionand 7% in a low dose low gradient region respectively.The average percentage of points passing the gammacriteria of 3% DD and 3 mm DTA for composite planardose distribution measured using I’MatriXX array was99.47 ± 0.43 which corresponds to a confidence limit of1.38 (i.e., 98.62% passing). Similarly, average percentageof points passing gamma for per-field dose distributionmeasured using EPID was 98 ± 2.49 which correspondsto a confidence limit of 6.87 (i.e., 93.13% passing). AAPMTG119 has not recommended the action levels for perfield dose measurement using EPID and array detectors.It is reasonable to assume that action levels for per fielddose measurement using EPID and array detectorsshould not be worse than the radiographic filmmeasured results reported by TG119. Our results werewell within action levels given in TG119 reportproviding us adequate confidence in delivering IMRTtreatment. However, large sample sizes are suggestedfor better statistical accuracy.
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